Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Flu-based COVID-19 Vaccine


總結

It is a flu-based nasal spray COVID-19 vaccine that could generate immunity against both flu and COVID-19.


技術優勢

Easy to use; Highly safe; provide both mucosal and systemic immune response


技術應用

Vaccine


詳細技術說明

It is live attenuated with the deletion of the key virulent element and immune antagonist, NS1, from the viral genome and is potentially more immunogenic than wild type influenza virus. It uses flu vector to express a specific antigen to induce immunity targeting the critical element of the Receptor Binding Domain (RBD) of SARS-CoVs. Such strategy may avoid potential antibody dependent enhancement (ADE) as observed in the experimental vaccine for SARS-CoV.
It can be produced in chicken embryonated eggs and MDCK cells which are proven production systems for influenza vaccines. Its features are highly safe and is used as nasal spray to induce both local mucosal immune response and systemic immune response by simulating the natural infection pathway of respiratory viruses.


合作類型

Licensing


申請日期

10/02/2020 00:00:00


申請號碼

US Provisional Application No. 62/972,616;

US Provisional Application No.63/037,645;

PCT/CN2021/075527


分類

C09D 5/00


國家/地區

香港

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版